Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Share-based Compensation for 10 consecutive years, with $37.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 6.65% to $37.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.0 million through Dec 2025, down 3.16% year-over-year, with the annual reading at $153.0 million for FY2025, 3.16% down from the prior year.
  • Share-based Compensation for Q4 2025 was $37.5 million at Ultragenyx Pharmaceutical, up from $37.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $41.6 million in Q3 2024, with the low at $24.3 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $34.1 million, with a median of $35.3 million recorded in 2022.
  • The sharpest move saw Share-based Compensation soared 32.69% in 2021, then decreased 10.97% in 2025.
  • Over 5 years, Share-based Compensation stood at $26.8 million in 2021, then increased by 9.35% to $29.4 million in 2022, then rose by 14.23% to $33.5 million in 2023, then increased by 19.69% to $40.1 million in 2024, then dropped by 6.65% to $37.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $37.5 million, $37.0 million, and $38.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.